Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis

Conclusions: Nimotuzumab is an effective treatment option for locoregionally advanced nasopharyngeal carcinoma, and the addition of induction chemotherapy to concurrent chemoradiotherapy and nimotuzumab could obtain the best survival benefits.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Fangzheng Wang, Quanquan Sun, Chuner Jiang, Tongxin Liu, Aizawa Rihito, Sakamoto Masoto, Yuezhen Wang, Zhenfu Fu, Ming Chen Tags: Research Paper Source Type: research